Vera Therapeutics Inc (VERA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.95B
Last updated: Nov 17, 2026 at 4:30 PM ET
Vera Therapeutics Inc (VERA) Statistics
Vera Therapeutics (VERA) has a market cap of $1.95B and an enterprise value of $1.97B. It kept -4041.19% of revenue as net income over the last 12 months. Its share count is up 12.97% from a year earlier.
Total Valuation
Enterprise value is 1.03% above the market cap, as debt exceeds cash.
| Market Cap | $1.95B |
|---|---|
| Enterprise Value | $1.97B |
| Latest price (Nov 17, 2026) | $26.20 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 183.9x and 5.7x.
| P/S Ratio | 183.9x |
|---|---|
| Forward P/S | 62.5x |
| P/B Ratio | 5.7x |
| P/TBV Ratio | 6.0x |
Price Statistics
The stock is down 7.58% over 52 weeks and trades 14.80% below its 50-day average.
| Beta (1Y) | 1.25 |
|---|---|
| 52-Week Change | -7.58% |
| 1-Month Change | -9.41% |
| 3-Month Change | -18.82% |
| 6-Month Change | -21.20% |
| 5-Year Change | +60.10% |
| Total Return (1Y) | -7.58% |
| Total Return (3Y CAGR) | +24.15% |
| Total Return (5Y CAGR) | -1.62% |
| Return vs SPY (1Y) | -20.93% |
| Max Drawdown (1Y) | -52.94% |
| Max Drawdown (3Y) | -62.09% |
| Sharpe Ratio (1Y) | -0.17 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $30.75 |
| 200-Day Average | $35.97 |
| 52-Week Range | $26.38 to $56.05 |
| RSI (14 Days) | 35.6 |
| Average Volume (20 Days) | 1.53M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.91x current liabilities, and total debt is 0.23x shareholder equity.
| Current Ratio | 7.91x |
|---|---|
| Quick Ratio | 7.78x |
| Debt / Equity | 0.23x |
| Interest Coverage | -57.65x |
Returns and Efficiency
Return on invested capital is -83.02% over the last 12 months, against a 5-year average of -46.60%.
| Return on Equity (ROE) | -124.65% |
|---|---|
| Return on Assets (ROA) | -89.17% |
| Return on Invested Capital (ROIC) | -83.02% |
| ROE (5Y Average) | -66.60% |
| ROA (5Y Average) | -45.07% |
| ROIC (5Y Average) | -46.60% |
| Asset Turnover | 0.02x |
| Inventory Turnover | 0.93x |
| Receivables Turnover | 1.72x |
| Cash Conversion Cycle | -1319 days |
Scores
VERA has an Altman Z-Score of 3.26, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.26 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $10.28M over the last 12 months.
| Revenue | $10.28M |
|---|---|
| Gross Profit | $8.11M |
| Operating Income | -$427.53M |
| Pretax Income | -$415.31M |
| Net Income | -$415.31M |
| Reported EPS (TTM) | -$5.90 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 71.54% of the $465.75M in total assets.
| Cash and Equivalents | $55.32M |
|---|---|
| Total Debt | $75.43M |
| Net Debt | $20.11M |
| Net Debt Per Share | $0.28 |
| Working Capital | $385.51M |
| Shareholder Equity | $333.19M |
| Book Value Per Share | $4.62 |
| Tangible Book Value | $312.69M |
| Tangible Book Per Share | $4.34 |
| Total Assets | $465.75M |
| Total Liabilities | $132.57M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$375.92M |
|---|---|
| FCF Per Share | -$5.22 |
| Depreciation and Amortization | $2.76M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -4160.07%.
| Gross Margin | 78.89% |
|---|---|
| Operating Margin | -4160.07% |
| Pretax Margin | -4041.18% |
| Net Margin | -4041.19% |
Growth
| Book Value Per Share Growth (2Y CAGR) | +102.88% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +102.88% |
Dividends and Yields
VERA does not pay a dividend.
| Buyback Yield | -16.60% |
|---|---|
| Shareholder Yield | -16.60% |
Peer Position
Against 7 similar companies, VERA has the highest P/S.
P/S RatioPeer median 7.4x
ROICPeer median -29.73%
| P/S Ratio | 183.9x vs 7.4x median |
|---|---|
| ROIC | -83.02% vs -29.73% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About VERA
What is VERA's market cap?
Vera Therapeutics has a market cap of $1.95B. Its enterprise value, which adds debt and subtracts cash, is $1.97B.
How many shares of VERA are outstanding?
Vera Therapeutics has 72.13M shares outstanding. The count is up 12.97% from a year earlier.
Does VERA pay a dividend?
No. Vera Therapeutics does not pay a dividend.
How much debt does VERA have?
Vera Therapeutics has $75.43M of total debt and $55.32M of cash and equivalents, a net debt position of $20.11M.
VERA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors